Cantor Fitzgerald Comments on Atyr PHARMA FY2024 Earnings

Atyr PHARMA INC (NASDAQ:ATYR - Free Report) - Analysts at Cantor Fitzgerald issued their FY2024 earnings per share estimates for shares of Atyr PHARMA in a research note issued to investors on Thursday, January 9th. Cantor Fitzgerald analyst P. Agrawal expects that the company will post earnings per share of ($0.91) for the year. Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Atyr PHARMA's current full-year earnings is ($0.89) per share.

Atyr PHARMA (NASDAQ:ATYR - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.01).

ATYR has been the topic of several other research reports. HC Wainwright reaffirmed a "buy" rating and issued a $35.00 price target on shares of Atyr PHARMA in a research note on Tuesday, December 10th. Wells Fargo & Company began coverage on Atyr PHARMA in a report on Friday, October 4th. They issued an "overweight" rating and a $17.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $19.25.

Atyr PHARMA Stock Down 5.6 %

Shares of NASDAQ ATYR opened at $3.53 on Monday. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02. The stock has a 50 day simple moving average of $3.36. The company has a market cap of $296.32 million, a P/E ratio of -3.76 and a beta of 1.08. Atyr PHARMA has a 12 month low of $1.39 and a 12 month high of $4.22.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Atyr PHARMA stock. JPMorgan Chase & Co. grew its holdings in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) by 52.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 31,440 shares of the company's stock after buying an additional 10,754 shares during the period. JPMorgan Chase & Co.'s holdings in Atyr PHARMA were worth $55,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 61.72% of the company's stock.

Atyr PHARMA Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.